A new study from Auburn University provides new insights into neuronal connections, offering hope for the treatment of ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Zunveyl (benzgalantamine) is now available for the treatment of mild to moderate dementia of the Alzheimer type in adults.

For individuals with dominantly inherited Alzheimer disease, long-term treatment with gantenerumab may delay clinical decline ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Panelists discuss how health care institutions are leveraging strategic referral networks and telemedicine technologies to bridge geographical barriers, connect rural patients with specialized ...

Panelists discuss how overcoming barriers to effective Alzheimer disease cognitive screening requires addressing multiple challenges including time constraints in clinical settings, inadequate ...

The type of work that requires this type of processing in the brain might help guard against Alzheimer's disease.

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

TRICARE addressed a critical coverage gap by approving provisional coverage of a new type of drug for the treatment of early ...

An experimental treatment appears to postpone Alzheimer's symptoms in some people genetically destined to get the disease at ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...